









Markets
/
Stocks
/
nasdaq-arvn
/

Arvinas Inc

ARVN

13.480USD

+0.520+4.01%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

954.38MMarket Cap

LossP/E TTM



Arvinas Inc

13.480

+0.520+4.01%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Arvinas Inc

Currency: USD Updated: 2026-02-06

Key Insights

Arvinas Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 68 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.24.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Arvinas Inc's Score

Industry at a Glance

Industry Ranking

68 / 392

Overall Ranking

188 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Arvinas Inc Highlights

StrengthsRisks

Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 100.46% year-on-year.

Undervalued

The company’s latest PE is -16.62, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 61.93M shares, decreasing 4.61% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 582.00 shares of this stock.

Analyst Rating

Based on 20 analysts

Buy

Current Rating

13.235

Target Price

+2.12%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Arvinas Inc is 6.11, ranking 287 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 41.90M, representing a year-over-year decrease of 59.08%, while its net profit experienced a year-over-year decrease of 28.66%.

Score

Industry at a Glance

Previous score

6.11

Change



Financials

7.26

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.26

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.12

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.10

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Arvinas Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Arvinas Inc is 8.32, ranking 51 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -16.62, which is -84.52% below the recent high of -2.57 and -2.60% above the recent low of -17.05.

Score

Industry at a Glance

Previous score

8.32

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 68/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Arvinas Inc is 7.40, ranking 293 out of 392 in the Biotechnology & Medical Research industry. The average price target is 14.00, with a high of 21.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

7.40

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 20 analysts

Buy

Current Rating

13.235

Target Price

+2.12%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Arvinas Inc

ARVN

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Arvinas Inc is 6.48, ranking 235 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 14.49 and the support level at 12.11, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.21

Change

0.27

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.041

Buy

RSI(14)

58.445

Neutral

STOCH(KDJ)(9,3,3)

48.847

Sell

ATR(14)

0.709

High Vlolatility

CCI(14)

52.044

Neutral

Williams %R

28.448

Buy

TRIX(12,20)

0.498

Sell

StochRSI(14)

42.720

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

13.462

Buy

MA10

13.391

Buy

MA20

12.852

Buy

MA50

12.450

Buy

MA100

11.011

Buy

MA200

9.237

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Arvinas Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 168.36%, representing a quarter-over-quarter increase of 11.84%. The largest institutional shareholder is The Vanguard, holding a total of 7.21M shares, representing 11.23% of shares outstanding, with 1.84% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

8.55M

-8.87%

BlackRock Institutional Trust Company, N.A.

5.17M

-1.65%

Pfizer Inc

3.46M

D. E. Shaw & Co., L.P.

3.41M

+1.73%

Logos Global Management LP

2.50M

-55.16%

Millennium Management LLC

2.13M

+12.30%

State Street Investment Management (US)

1.87M

+8.13%

Geode Capital Management, L.L.C.

1.67M

+5.37%

TCG Crossover Management, LLC

1.62M

New Leaf Venture Partners LLC

1.59M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Arvinas Inc is 4.89, ranking 63 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.